Lineage Cell Therapeutics, Inc.

LCTX

Explore Our Financial Data > Companies > Lineage Cell Therapeutics, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	LCTX
CIK	0000876343
SIC	2836
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Biological Products, Except Diagnostic Substances

Contact

Address	2173 SALK AVENUE, SUITE 200, CARLSBAD, CA, 92008
Website	lineagecell.com
Phone	5105213390
CEO	Brian M. Culley
Employees	60

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$9.56 million
Pre-Tax Income	$-16.17 million
Net Income	$-16.17 million
Net Income to Common	$-16.21 million
EPS	$-0.07

View All

Balance Sheet

Cash	$47.89 million
Assets	$111.75 million
Liabilities	$34.10 million
Common Equity	$79.03 million
Liabilities & Equity	$111.75 million

View All

Cash Flow Statement

Net Income	$-16.17 million
Cash From Operating Activities	$-22.20 million
Cash From Investing Activities	$-367,000.00
Cash From Financing Activities	$26.88 million
Change in Cash	$4.32 million

View All

Calculations

NOPAT	$-14.93 million
EBITDA	$-17.30 million
Price to Earnings	N/A
Price to Book	$2.75
ROE	-21.75%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium

CARLSBAD, Calif., June 05, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, today announced additional presenters to the 3rd Annual Spinal Cord Injury Investor Symposium ("3rd SCIIS"). The 3rd SCIIS will be a fully virtual event, with interactive and on-demand sessions available starting on June 27, 2025.

Article Link

Q1 2025 Lineage Cell Therapeutics Inc Earnings Call

Article Link

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

CARLSBAD, Calif., May 14, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, in a fireside chat hosted by Joseph Pantginis, Ph.D., Managing Director, Equity Research, on Tuesday, May 20, 2025, at 2:30pm ET. The 3rd Annual

Article Link

Lineage Cell Therapeutics Inc (LCTX) Q1 2025 Earnings Call Highlights: Strategic Advances and ...

Lineage Cell Therapeutics Inc (LCTX) reports a strong cash position and significant manufacturing milestones, despite ongoing financial challenges.

Article Link

Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

Lineage Cell (LCTX) delivered earnings and revenue surprises of 0% and 31.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Article Link